Tiny Altimmune is slinging stones at the goliaths of the obesity market. Facing well-set incumbents, the biotech pitched its midphase data as evidence that its GLP-1 candidate can carve out a niche in obesity patients at risk of cardiovascular events—but tolerability issues that marred an earlier data drop remain.
After developing a wearable device that can automatically detect seizures in people with epilepsy and immediately notify their caregivers, Empatica is planning to take the technology even further.
Phenomic AI has largely lived off the grid since launching more than three years ago, but it’s now sprinting onto the scene with a second collaboration in as many days, this time with Astellas.
Several months after earning FDA clearance, a 3D-printed bone graft product is gaining steam, having now been used in a handful of surgical procedures.
Tang Capital Partners’ Concentra Biosciences is back with yet another biotech buyout offer, this time proposing to acquire LianBio in a cash deal of $4.30 per share.
A new healthcare-medtech team-up is aiming to build high-tech imaging tools to improve disease diagnoses and patient outcomes.
Pfizer cans twice-daily oral obesity program after half of patients leave trial while once daily continues
Pfizer is continuing to pinball between oral obesity assets. Months after making twice-daily danuglipron its top prospect, the Big Pharma has dropped the program after more than half of people taking the drug candidate dropped out of a midphase clinical trial.
If I had a nickel for each time in the past 48 hours a major medtech announced moves in heart implants aimed at reducing a person’s risk of stroke, I’d have two nickels.
Antiretroviral therapy, or ART, has made it possible for HIV-positive people to live just as long as those without the virus. But though their lifespans may be equal, healthspans are another matter: People with HIV start experiencing chronic health problems, like liver and heart disease, an average of 16 years earlier than their HIV-negative peers.
Cybin has put out more data on its psychedelic treatment for depression, presenting findings from a phase 2 trial that suggest there may be benefits to repeat administration but not to increasing the dose.